Christopher Mason

Professor

Weill Cornell Medical College
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (36)

Detecting low variant allele fraction (VAF) mosaic variants without matching controls remains a major challenge in genomics, limited by technical noise, lack of benchmarks, and computational scalability. We present the DRAGEN mosaic caller, a hardware-accelerated approach identifying variants down to ∼1-2% VAF with low false-positive rates and hour-scale runtimes for mosaic SNV/indel detection from bulk sequencing. To support evaluation, we introduce a genome-wide low-VAF benchmark for variants between 1-10% VAF. Application to blood, sperm, and brain tissues revealed patterns, including mosaic hotspots and mutational signatures. The first analysis of HG002 blood showed that many “mosaic” variants defined from HG002 cell lines are likely culture-derived and not in vivo mutations. Importantly, DRAGEN also enables personalized assembly pangenome references to improve alignment and mosaic variant detection in complex regions. Together, this development makes routine low-VAF discovery feasible, opening new opportunities to study mosaic mutations in healthy and disease individuals.

Year:

2026

Disparities in formal bioinformatics training exacerbate the global skills gap, impeding the democratized application of advanced genomic technologies. To bridge this divide, we introduce a scalable, hybrid training framework designed to rapidly accelerate regional bioinformatics capacity. We exemplify this approach through the Eastern European Bioinformatics and Genomics (EEBG) workshop series — a cross-disciplinary initiative that pairs international faculty with local institutions to deliver modular, hands-on curricula. Functioning as a structured knowledge-transfer pipeline, the series has catalyzed a sustainable educational ecosystem, evidenced by the establishment of multiple independent summer schools across the region. The assessment of the 2025 EEBG workshop in Kraków, Poland, validates the model’s viability; participant metrics confirm high efficacy in skill acquisition (mean satisfaction: 4.4/5.0) and community building. Crucially, the hybrid delivery mode dismantled geographic barriers, serving as a vital mechanism for maintaining scientific continuity for researchers facing displacement and crisis. Synthesizing these outcomes, we define the core features of a replicable blueprint for scientific readiness in resource-constrained environments. We conclude by presenting a strategic roadmap — organized around infrastructure standardization, governance sustainability, and geographical expansion — for adapting this regional proof-of-concept into a global export-ready model, offering a critical path toward ensuring universal access to genomic innovation.

Year:

2026

Ferritin, consisting of ferritin heavy chain (FTH1) and light chain (FTL) subunits, is an essential intracellular iron storage protein fundamental for cellular function. However, the source and the biological role of extracellular ferritin (ex-ferritin) are less understood. Recent studies have linked elevated serum ex-ferritin with adverse outcomes in individuals with acute respiratory distress syndrome (ARDS). In this study, we demonstrate that both FTH1 and FTL are significantly enriched in the serum, blood monocytes, and alveolar macrophages (AMs) of individuals with ARDS, a phenomenon we successfully replicate in a murine hyperoxia-induced acute lung injury (HALI) model. We show that FTH1 is consistently upregulated in macrophages during lung injury development, and mice with a targeted deletion of FTH1 in myeloid (LysMcre) or resident lung macrophage (Cd11ccre) populations exhibit attenuated HALI. This reduced injury is linked to macrophage resistance to ferroptotic cell death, ferritinophagy, altered airway inflammatory responses, and lower lung extracellular iron and higher levels of FTL-ex-ferritin. Transplantation of FTL-ex-ferritin-enriched bronchoalveolar lavage fluid to wild-type mice protected against HALI. The ratio of FTL-ex-ferritin to FTH1 in the serum of individuals with ARDS who died was higher than that of those that survived, suggesting that the balance between FTH1 and FTL may play a role in injury modulation. Our findings highlight macrophage ferritin as a key regulator of macrophage survival and the response of the lung to injury, presenting a potentially targetable pathway for ARDS treatment.

Year:

2026

Inconsistent cellular lysis is a major source of inaccuracy in microbial analysis; there is a need to develop objective and standardized evaluation of lysis efficiency across diverse methods. Using a mock microbial community as a ground truth, we built a bioinformatic and experimental toolkit for this purpose, comparing the performance of chemical, thermal, enzymatic, and various physical lysis protocols. We evaluated over 150 lysis conditions and observed the highest performance from mechanically- and materially-optimized bead-based approaches. To extend these findings to a practical setting, we demonstrated that the Firmicutes to Bacteroides ratio, a frequently used compositional metric in gut microbiome analysis is biased heavily by insufficient lysis, indicating the importance of benchmarking ongoing methodological development.

Year:

2026

After the COVID-19 pandemic, wastewater monitoring is increasingly used for infectious disease surveillance. Using the data from a controlled experimental hospital setting, this paper examines the association wastewater SARS-CoV-2 with COVID-19 hospital admission and mortality, and whether this association varies by patients’ characteristics. Weekly wastewater samples were collected from the University of Miami (UM) hospitals where COVID-19 patients were admitted from February 2020 to October 2022, and SARS-CoV-2 was quantified using qPCR. Data on hospital admissions and their mortality and demographic characteristics and comorbidities were acquired from the UM hospitals. Using factor analysis and hierarchical clustering, patients were stratified into four clusters. Frist, we examined cross-correlations between time-lagged COVID-19 hospital admission and mortality, and time-lagged SARS-CoV-2 to identify appropriate time-lags. Second, we modelled daily hospital COVID-19 cases and mortality with respect to time-lagged SARS-CoV-2, vaccine status and time-lagged COVID-19 hospital cases (as proxy of the risk factor for the transmission of the disease for each cluster separately and for all clusters together. 1,856 COVID-19 patients were admitted in the UM hospitals during the study period and 347 (18.7%) of them died. In cluster 4 that represented patients with preexisting chronic health conditions and intubation, the fatality rate was 59%. COVID-19 hospital admission showed strong (temporal) autocorrelation, suggesting that the preexisting cases can indicate the transmission rate of infection. Our analysis suggests that a 1% increase in SARS-CoV-2 was associated with a 0.28% increase in COVID-19 related hospital admission (β ∼ 0.275; 95 % CI = 0.18 to 0.37; p < 0.01). Both a week lagged auto-regressive COVID-19 cases and SARS-CoV-2 in wastewater together explained 89% of the total variation in hospital admission due to COVID-19. Among four clusters, the second cluster of minority communities showed the strongest association between time-lagged SARS-CoV-2 in wastewater and hospital admissions due to COVID-19 followed by cluster 1 of adult patients with low prevalence of preexisting health conditions. However, time-lagged wastewater SARS-CoV-2 did not show any significant association with COVID-19 hospital admission for patients with the pre-existing health conditions. A week lagged wastewater SARS-CoV-2 did not show any significant association with COVID-19 mortality. Our results indicate that the association between time-lagged wastewater SARS-CoV-2 and COVID-19 hospital admission varied by patients’ characteristics, suggesting variations in SARS-CoV-2 shedding by patients’ characteristics. These findings warrant to incorporate patient-specific demographic characteristics and comorbidities in modelling infectious diseases surveillance using wastewater monitoring of the infectious agents.

Year:

2025

Traditional epigenetic aging clocks are limited because they do not incorporate clinical information and functional tests, and rely on DNA samples and methylation profiling infrastructure which are not easily accessible. To address these limitations, we built a new framework, FusionAge, with which we trained 26 aging clocks using interpretable nonlinear models, including deep neural networks (DNNs). Our results show that multimodal clocks built with DNNs significantly outperform clocks derived from single modalities or traditional linear models. FusionAge-derived biological age is more strongly associated with incident disease and mortality compared to chronological age in UK Biobank individuals. We validated these findings in the National Health and Nutrition Examination Survey, confirming that cardiorespiratory fitness is a major, consistent driver of biological age. Finally, we applied FusionAge to demonstrate its utility in detecting biological age changes in astronauts following spaceflight. Together, we demonstrate a powerful, portable framework for assessing biological age that captures the complex, multifactorial nature of human aging.

Year:

2025

Purpose: Mantle cell lymphoma (MCL) remains incurable despite therapeutic advances, highlighting the need for improved preclinical models. Existing transgenic MCL mouse models have significant limitations, restricting their translational value. Experimental Design: We generated an immunocompetent MCL model by overexpressing the key oncogenic drivers SRY-box transcription factor 11 ( SOX11 ) and Cyclin D1 ( CCND1) under the Eµ enhancer in C57BL/6 mice, aiming to replicate human MCL’s biological and pathologic features. Results: Eµ-SOX11CCND1 mice developed lymphoma marked by clonal B1a cell expansion in lymphatic and extranodal tissues. Morphologic, immunophenotypic, and transcriptional profiling revealed strong similarity to human MCL, with pathway analysis confirming significant molecular overlap. Importantly, lymphoma cells could be adoptively transferred into wild-type recipients, enabling therapeutic testing within an intact immune system. Conclusions: The Eµ-SOX11CCND1 mouse represents a robust and biologically relevant model that faithfully recapitulates human MCL. Its immunocompetent nature and adoptive transfer capability make it a valuable model for studying disease mechanisms and evaluating novel therapeutic approaches for patients with MCL.

Year:

2025

Myelodysplastic neoplasms (MDS) are genetically heterogeneous hematopoietic malignancies characterized by ineffective hematopoiesis, peripheral cytopenias, and risk of progression to acute myeloid leukemia. Diagnosis relies on subjective histomorphologic evaluation of bone marrow biopsies, leaving the significance of subtle microarchitectural changes unclear. We applied an AI-driven, whole-slide imaging–based multiplex immunofluorescence single-cell spatial phenotyping approach to diagnostic MDS samples (n=36), serial biopsies (n=29), precursor-state samples (n=13), and normal controls (n=21), profiling over 5 million cells. Compared with age-matched controls, MDS exhibited altered progenitor cell frequencies, abnormal erythroid and megakaryocyte morphology, disrupted erythroid islands, vascular displacement of hematopoietic stem and progenitor cells, and aberrant progenitor cell clustering. Several features correlated more strongly with specific mutations (e.g., SF3B1 , TP53 ) than with IPSS-M risk scores. We integrated these features into a composite MDS Microarchitectural Perturbation Score (MDS-MAPS) that aligned with clinical and genetic parameters across serial samples, revealing previously unrecognized, genotype-associated microarchitectural alterations in MDS. SIGNIFICANCE AI-driven spatial mapping detects previously unrecognized microarchitectural perturbations in MDS patient bone marrow biopsy tissues. Microarchitectural perturbations track closely with clinical and genetic parameters during the course of disease-modifying therapy. The detection of these features holds the potential to additionally inform clinical evaluation alongside standard clinical parameters.

Year:

2025

The transmission of the paternal genome requires extensive chromatin reorganization, in which nucleosomes are largely replaced by protamines that drive extreme condensation of the genome in the sperm head. Using Fiber-seq, we resolve patterns of paternal chromatin repackaging in sperm at single-molecule resolution, revealing the interplay between protamination and nucleosome retention. We find that nucleosome retention is probabilistic, with no locus universally occupied. Although promoters of spermatogenic genes preferentially harbor retained nucleosomes, the predominant carrier of paternal epigenetic information is protamine lacunae, accessible discontinuities in the protamine coat that preferentially mark critical regulatory elements. By contrast, centromere kinetochore binding regions robustly retain CENP-A mono-nucleosomes, providing a mechanism for the focal transmission of paternal centromeres. Finally, we find that paternal chromatin repackaging is altered in low-motility sperm. Together, these findings reveal distinct modes of paternal chromatin epigenetic inheritance with broad implications for development and infertility.

Year:

2025

Gliomas are a type of CNS tumors. Protein arginine methyltransferases (PRMTs) play important epigenetic regulatory roles in various cancers, including gliomas, by regulating DNA repair and cellular signaling pathways. Recent studies have also identified overexpression of PRMTs in gliomas and have shown that it is associated with tumor progression and resistance to conventional therapies. Targeting PRMTs has shown promising preclinical results demonstrating the potential to disrupt tumor growth, enhance DNA damage responses, and improve the sensitivity of gliomas to radiotherapy and temozolomide. In this review, we focus on the translational and clinical relevance of PRMT inhibitors in glioma subtypes, highlighting their latest clinical developments and ongoing clinical trials. Unlike previous reviews, our article provides an updated synthesis of clinical data, discusses challenges and opportunities in clinical translation, and suggests future directions for integrating PRMT inhibitors into glioma therapy.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (102)

Mayumi Sugita

Weill Cornell Medicine

UNITED STATES
View details

Cem Meydan

Assistant Professor

Weill Cornell Medicine

UNITED STATES
View details

Karla Ballman

Chair / Consultant / Professor of Biostatistics

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Andrew Stergachis

University of Washington

UNITED STATES
View details

george church

Professor

Harvard Medical School

UNITED STATES
View details

David Furman

Professor and Director AI & Bioinformatics Core; Head of Stanford 1,000 Immunomes Project

Buck Institute for Research on Aging

UNITED STATES
View details

Olivier Elemento

Professor

Weill Cornell Medical College

UNITED STATES
View details

Elinor Karlsson

Associate Professor

University of Massachusetts Chan Medical School

UNITED STATES
View details

Walter Hanel

Ohio State University

UNITED STATES
View details

Sylvain Costes

Professor

University of Pittsburgh

UNITED STATES
View details

Jonathan Schisler

Assistant Professor

University of North Carolina at Chapel Hill School of Medicine

UNITED STATES
View details

Robert Baiocchi

-

UNITED STATES
View details

Serghei Mangul

University of Southern California

UNITED STATES
View details

David W. Scott

The University of British Columbia

CANADA
View details

Andrea Guarracino

Assistant Professor

Translational Genomics Research Institute

UNITED STATES
View details

Sonja Scholz

National Institute of Neurological Disorders and Stroke

UNITED STATES
View details

JangKeun Kim

Senior Research Associate

Weill Cornell Medicine

UNITED STATES
View details

Fritz Sedlazeck

Associate Professor

Baylor College of Medicine

UNITED STATES
View details

Masafumi Muratani

Professor

University of Tsukuba

JAPAN
View details

Rosa Lapalombella

Ohio State University

UNITED STATES
View details

Gero Knittel

University Hospital Essen

GERMANY
View details

Helena Solo-Gabriele

Professor

University of Miami

UNITED STATES
View details

Heer Mehta

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Julie A. Meachen

Professor

Des Moines University

UNITED STATES
View details

Dmitriy Zamarin

Professor and Section Head, Gynecologic Medical Oncology

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Wendy Béguelin

Assistant Professor

NYU School of Medicine

UNITED STATES
View details

Erik Garrison

Associate Professor

University of Tennessee Health Science Center

UNITED STATES
View details

Dylan McNally

Cornell University

UNITED STATES
View details

Francisco J. Enguita

Director

Universidade de Aveiro

PORTUGAL
View details

Justin Zook

National Institute of Standards and Technology

UNITED STATES
View details

W. Scott Watkins

University of Utah

UNITED STATES
View details

Massimo Loda

Chair

Weill Cornell Medical College

UNITED STATES
View details

Steven Lipkin

Associate Professor

Weill Cornell Medical College

UNITED STATES
View details

Jean Calleja Agius

Head of Department, Associate Professor

University of Malta

View details

Bluma J Lesch

Associate Professor

Yale University

UNITED STATES
View details

Minkyung Song

Assistant Professor

Sungkyunkwan University

SOUTH KOREA
View details

Love Dalén

Professor

Stockholm University

SWEDEN
View details

Monica L. Guzman

-

UNITED STATES
View details

Suzanne Cloonan

Associate Professor in Respiratory Biochemistry

Weill Cornell Medicine

UNITED STATES
View details

Naresh Kumar

Teaching and Research, Associate Professor

University of Miami

UNITED STATES
View details

Edward Schenck

Assistant Professor of Medicine

Cornell University

UNITED STATES
View details

Martin Hölzer

Robert Koch Institute

GERMANY
View details

Lapo Alinari

Ohio State University

UNITED STATES
View details

Evan Eichler

Howard Hughes Medical Institute

UNITED STATES
View details

Jiwoon Park

Weill Cornell Medicine

UNITED STATES
View details

Satishkumar Singh

Ohio State University

UNITED STATES
View details

Oona Shigeno Risse-Adams

Cornell University

UNITED STATES
View details

Oleksyk Taras

Assistant Professor

Oakland University

UNITED STATES
View details

Amal Thomas

University of Southern California

UNITED STATES
View details

Juan Cubillos-Ruiz

Professor of Microbiology and Immunology

Weill Cornell Medicine

UNITED STATES
View details

Samir Parekh

Director, Center of Excellence for Multiple Myeloma

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Robert Schwartz

Associate Professor

Weill Cornell Medicine

UNITED STATES
View details

Luciano Martelotto

A/Professor, Head of the Development Laboratory

Harvard University

UNITED STATES
View details

Brandi Cantarel

University of Texas Southwestern Medical Center

UNITED STATES
View details

Wing Keung Chan

Assistant Professor

Ohio State University

UNITED STATES
View details

Lawrence Grossman

Professor and Director

Wayne State University School of Medicine

UNITED STATES
View details

Greger Larson

University of Oxford

UNITED KINGDOM
View details

Joanna Polanska

Professor of Bioinformatics, Head of the Department

Silesian University of Technology

POLAND
View details

Diana K. Morales

Associate Professor of Microbiology

Weill Cornell Medical College

UNITED STATES
View details

Carlos Flores

Universidad de la Laguna

SPAIN
View details

Glennis Logsdon

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Deepika Awasthi

Weill Cornell Medicine

UNITED STATES
View details

Robert Faryabi

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Marcus Gilbert

Københavns Universitet

DENMARK
View details

Melissa Frey

Associate Professor

Weill Cornell Medicine

UNITED STATES
View details

Afshin Beheshti

Professor

University of Pittsburgh

UNITED STATES
View details

Nathanael Olson

National Institute of Standards and Technology

UNITED STATES
View details

Anna Vähärautio

University of Helsinki

FINLAND
View details

Matias Marin Falco

University of Helsinki

FINLAND
View details

David Porubsky

-

UNITED STATES
View details

John McDonald

Assistant Professor (Adjunct Track)

Georgetown University

UNITED STATES
View details

Rachel J. O’Neill

University of Connecticut

UNITED STATES
View details

Nathaniel Szewczyk

Professor

Ohio State University

UNITED STATES
View details

Wanqiu Chen

Research Assistant Professor

Loma Linda University

UNITED STATES
View details

Sara Zwart

University of Texas Medical Branch

UNITED STATES
View details

Evelyn Cantillo

Weill Cornell Medicine

UNITED STATES
View details

Alexander Zelikovsky

Distinguished University Professor

University of Georgia

UNITED STATES
View details

christos proukakis

Professor of Neurology and Neurogenetics

University College London

UNITED KINGDOM
View details

Lorenzo Galluzzi

-

UNITED STATES
View details

Jennifer McDaniel

National Institute of Standards and Technology

UNITED STATES
View details

qiang pan-hammarstrom

Professor, head of the Immunology Division

Karolinska University Hospital

SWEDEN
View details

Evanthia Roussos Torres

Assistant Professor

University of Southern California Norris Comprehensive Cancer Center

UNITED STATES
View details

Paweł Łabaj

dr hab. inż., prof. UJ

Jagiellonian University

POLAND
View details

Joshua Fein

Assistant prof

Weill Cornell Medicine

UNITED STATES
View details

Harriet Dashnow

Assistant Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Yan Guo

University of Miami

UNITED STATES
View details

Karl Koehler

Assistant Professor

Harvard Medical School

UNITED STATES
View details

Lalit Sehgal

Associate Professor

Ohio State University

UNITED STATES
View details

Chaz Hyseni

Uppsala University

SWEDEN
View details

Charles Wang

Professor/Director

Loma Linda University

UNITED STATES
View details

Hui-Hsuan Kuo

Northwestern University

UNITED STATES
View details

Jasmine Plummer

Director, Associate Member

St. Jude Children's Research Hospital

UNITED STATES
View details

Remi Klotz

Assistant Professor of Research

University of Maryland

UNITED STATES
View details

Violetta Leshchenko

Senior Scientist

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Charles Lee

Director and Professor

The Jackson Laboratory for Genomic Medicine

UNITED STATES
View details

Min Yu

Professor

-

UNITED STATES
View details

Hans Christian Reinhardt

-

GERMANY
View details

Sebastian E. Carrasco

Weill Cornell Medicine

UNITED STATES
View details

Bridgett M. Vonholdt

Associate Professor

Princeton University

UNITED STATES
View details

Bérénice Benayoun

Assistant Professor

University of Southern California

UNITED STATES
View details

Ari M. Melnick

Director

Josep Carreras Leukaemia Research Institute

SPAIN
View details

Paul C Boutros

University of California

UNITED STATES
View details